scholarly journals Efficacy and safety of adjunctive rasagiline in Japanese Parkinson's disease patients with wearing-off phenomena: A phase 2/3, randomized, double-blind, placebo-controlled, multicenter study

2018 ◽  
Vol 53 ◽  
pp. 21-27 ◽  
Author(s):  
Nobutaka Hattori ◽  
Atsushi Takeda ◽  
Shinichi Takeda ◽  
Akira Nishimura ◽  
Masafumi Kato ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Multicenter Study ◽  
Phase 2 ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Wearing Off

The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: A randomized, double-blind, placebo-controlled, multicenter study

2011 ◽  
Vol 26 (10) ◽  
pp. 1851-1858 ◽  
Author(s):  
Hasmet A. Hanagasi ◽  
Hakan Gurvit ◽  
Pınar Unsalan ◽  
Hilal Horozoglu ◽  
Nese Tuncer ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cognitive Deficits ◽  
Multicenter Study ◽  
Double Blind ◽  
Double Blind Placebo

Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double-blind, placebo-controlled multicenter study

2017 ◽  
Vol 32 (9) ◽  
pp. 1335-1336 ◽  
Author(s):  
Christopher G. Goetz ◽  
Glenn T. Stebbins ◽  
Kathryn A. Chung ◽  
Anthony P. Nicholas ◽  
Robert A. Hauser ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Multicenter Study ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial

2016 ◽  
Vol 15 (3) ◽  
pp. 249-258 ◽  
Author(s):  
Emily J Henderson ◽  
Stephen R Lord ◽  
Matthew A Brodie ◽  
Daisy M Gaunt ◽  
Andrew D Lawrence ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Phase 2 ◽  
Double Blind ◽  
Gait Stability ◽  
Double Blind Placebo ◽  
Phase 2 Trial
Sign in / Sign up

Export Citation Format

Share Document